Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is $3.88 (-3.5% Y/Y) and the consensus Revenue Estimate is ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...

Modernization of “manufacturing technologies and controls through further advanced automation and artificial intelligence” ...

One of North Carolina’s largest life sciences companies, Biogen Inc. (Nasdaq BIIB), is celebrating its 30th anniversary in ...

RESEARCH TRIANGLE PARK, N.C. (WTVD) -- Global biotechnology firm Biogen announced a major investment in its Research Triangle ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB ...

This was the stock's third consecutive day of losses.

Biogen Inc. is now projecting a better-than-expected 2024 as the company continues to see an uptick in sales from Leqembi, the Alzheimer's disease drug it developed in partnership with Eisai Inc.

Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant ...